Heart-brain signaling in patent foramen ovale-related stroke: Differential plasma proteomic expression patterns revealed with a 2-pass liquid chromatography-tandem mass spectrometry discovery workflow

Journal of Investigative Medicine

Volumn 60, Issue 8, 2012, Pages 1122-1130

  Lopez, Mary F ^a   Sarracino, David A ^a   Vogelsang, Maryann ^a   Sutton, Jennifer N ^a   Athanas, Michael ^a   Krastins, Bryan ^a   Garces, Alejandra ^a   Prakash, Amol ^a   Peterman, Scott ^a   Demirjian, Zareh ^b   Inglessis Azuaje, Ignacio ^b   Feeney, Kathleen ^b   Elia, Mikaela ^b   David McMullin, ^b   Dec, G William ^b   Palacios, Igor ^b   Lo, Eng H ^b   Buonanno, Ferdinand ^b   Ning, MingMing ^b  

^a Thermo Fisher Scientific   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Biomarker; Cerebrovascular disease; Discovery; Ischemic stroke; Mass spectrometry; Patent foramen ovale; PFO; Proteomics; Stroke

Indexed keywords

ALPHA 2 MACROGLOBULIN; ALPHA1 ANTITRYPSIN PRECURSOR; BIOLOGICAL MARKER; HEMOGLOBIN BETA CHAIN; LIVER X RECEPTOR; PROTEIN; PROTEOME; PROTHROMBIN; RETINOID X RECEPTOR; SEROTRANSFERRIN; SERUM ALBUMIN; SIMILAR TO IMMUNOGLOBULIN LAMBDA LIKE POLYPEPTIDE 1; UNCLASSIFIED DRUG;

ACUTE PHASE RESPONSE; ADULT; ATHEROSCLEROSIS; BLOOD CLOTTING; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; ENDOVASCULAR SURGERY; FEMALE; FUNCTIONAL PROTEOMICS; HUMAN; INFLAMMATION; LIQUID CHROMATOGRAPHY; MALE; PATENT FORAMEN OVALE; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; TANDEM MASS SPECTROMETRY; WORKFLOW; BLOOD CLOT; CELL SIGNALING ASSAY; MAJOR CLINICAL STUDY; PROTEOMICS; STROKE PATIENT; SYSTEMIC CIRCULATION;

ADULT; BRAIN; CHROMATOGRAPHY, LIQUID; COHORT STUDIES; FEMALE; FORAMEN OVALE, PATENT; GENE EXPRESSION REGULATION; HEART; HUMANS; MALE; MIDDLE AGED; PROTEOMICS; SIGNAL TRANSDUCTION; STROKE; TANDEM MASS SPECTROMETRY; YOUNG ADULT;

EID: 84871432184     PISSN: 17088267     EISSN: 17088267     Source Type: Journal    
DOI: 10.2310/JIM.0b013e318276de0e     Document Type: Conference Paper

References (52)

1. Calvert PA, Rana BS, Kydd AC, et al. Patent foramen ovale: anatomy, outcomes, and closure. Nat Rev Cardiol. 2011;8:148-160.
2. Ning M, Lo EH, Inglessis I, et al. The brain's heart-therapeutic opportunities for patent foramen ovale and neurovascular disease. Pharmacol Ther. 2012. In press.
3. Kunitz SC, Gross CR, Heyman A, et al. The pilot Stroke Data Bank: definition, design, and data. Stroke. 1984;15:740-746.
4. Foulkes MA, Wolf PA, Price TR, et al. The Stroke Data Bank: design, methods, and baseline characteristics. Stroke. 1988;19:547-554.
5. Sacco RL, Ellenberg JH, Mohr JP, et al. Infarcts of undetermined cause: the NINCDS Stroke Data Bank. Ann Neurol. 1989;25:382-390.
6. Adams HP Jr, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993;24:35-41.
7. Petty GW, Brown RD Jr, Whisnant JP, et al. Ischemic stroke subtypes: a population-based study of incidence and risk factors. Stroke. 1999;30:2513-2516.
8. Kolominsky-Rabas PL, Weber M, Gefeller O, et al. Epidemiology of ischemic stroke subtypes according to TOAST criteria: incidence, recurrence, and long-term survival in ischemic stroke subtypes: a population-based study. Stroke. 2001;32:2735-2740.
9. Lee BI, Nam HS, Heo JH, et al. Yonsei Stroke Registry. Analysis of 1,000 patients with acute cerebral infarctions. Cerebrovasc Dis. 2001;12:145-151.
10. Grau AJ, Weimar C, Buggle F, et al. Risk factors, outcome, and treatment in subtypes of ischemic stroke: the German stroke data bank. Stroke. 2001;32:2559-2566.
11. Schulz UG, Rothwell PM. Differences in vascular risk factors between etiological subtypes of ischemic stroke: importance of population-based studies. Stroke. 2003;34:2050-2059.
12. Schneider AT, Kissela B, Woo D, et al. Ischemic stroke subtypes: a population-based study of incidence rates among blacks and whites. Stroke. 2004;35:1552-1556.
13. Mohr J, Choi WC, Grotta JC, et al. Stroke: Pathophysiology, Diagnosis, and Management. New York: Churchill Livingstone; 2004.
14. Agmon Y, Khandheria BK, Meissner I, et al. Frequency of atrial septal aneurysms in patients with cerebral ischemic events. Circulation. 1999;99:1942-1944.
15. Pearson AC, Nagelhout D, Castello R, et al. Atrial septal aneurysm and stroke: a transesophageal echocardiographic study. J Am Coll Cardiol. 1991;18:1223-1229.
16. Mattioli AV, Aquilina M, Oldani A, et al. Atrial septal aneurysm as a cardioembolic source in adult patients with stroke and normal carotid arteries. A multicentre study. Eur Heart J. 2001;22:261-268.
17. Cabanes L, Mas JL, Cohen A, et al. Atrial septal aneurysm and patent foramen ovale as risk factors for cryptogenic stroke in patients less than 55 years of age. A study using transesophageal echocardiography. Stroke. 1993;24:1865-1873.
18. Webster MW, Chancellor AM, Smith HJ, et al. Patent foramen ovale in young stroke patients. Lancet. 1988;2:11-12.
19. Lechat P, Mas JL, Lascault G, et al. Prevalence of patent foramen ovale in patients with stroke. N Engl J Med. 1988;318:1148-1152.
20. Di Tullio M, Sacco RL, Gopal A, et al. Patent foramen ovale as a risk factor for cryptogenic stroke. Ann Intern Med. 1992;117:461-465.
21. Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and stroke statisticsV2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009;119:e21-e181.
22. Hara H, Virmani R, Ladich E, et al. Patent foramen ovale: current pathology, pathophysiology, and clinical status. J Am Coll Cardiol. 2005;46:1768-1776.
23. Hagen PT, Scholz DG, Edwards WD. Incidence and size of patent foramen ovale during the first 10 decades of life: an autopsy study of 965 normal hearts. Mayo Clin Proc. 1984;59:17-20.
24. Meissner I, Whisnant JP, Khandheria BK, et al. Prevalence of potential risk factors for stroke assessed by transesophageal echocardiography and carotid ultrasonography: the SPARC study. Stroke prevention: assessment of risk in a community. Mayo Clin Proc. 1999;74:862-869.
25. Pinto FJ. When and how to diagnose patent foramen ovale. Heart. 2005;91:438-440.
26. Sacco RL, Di Tullio MR, Homma S. Treatment of patent foramen ovale and stroke: to close or not to close, that is not yet the question. Eur Neurol. 1997;37:205-206.
27. Nendaz MR, Sarasin FP, Junod AF, et al. Preventing stroke recurrence in patients with patent foramen ovale: antithrombotic therapy, foramen closure, or therapeutic abstention? A decision analytic perspective. Am Heart J. 1998;135:532-541.
28. Donnan GA, Davis SM. Patent foramen ovale and stroke: closure by further randomized trial is required! Stroke. 2004;35:806.
29. Furlan AJ. Patent foramen ovale and recurrent stroke: closure is the best option: yes. Stroke. 2004;35:803-804.
30. Tong DC, Becker KJ. Patent foramen ovale and recurrent stroke: closure is the best option: no. Stroke. 2004;35:804-805.
31. Ferguson T, Sansing LH, Herrmann H, et al. To close or not to close: PFO, sex and cerebrovascular events. J Invasive Cardiol. 2006;18:E292-E293.
32. Windecker S, Meier B. Is closure recommended for patent foramen ovale and cryptogenic stroke? Patent foramen ovale and cryptogenic stroke: to close or not to close? Closure: what else! Circulation. 2008;118:1989-1998.
33. Kent DM, Thaler DE. The Risk of Paradoxical Embolism (RoPE) Study: developing risk models for application to ongoing randomized trials of percutaneous patent foramen ovale closure for cryptogenic stroke. Trials. 2011;12:185.
34. Furlan AJ, Reisman M, Massaro J, et al. Closure or medical therapy for cryptogenic stroke with patent foramen ovale. N Engl J Med. 2012;366:991-999.
35. Johnston SC. Patent foramen ovale closure. N Engl J Med. 2012;366:1048-1050.
36. Ning M, Navaratna D, Demirjian Z, et al. How the heart whispers to the brain: serotonin as neurovascular mediator in patent foramen ovale related stroke. Stroke. 2011;42:e108.
37. Yates JR, Ruse CI, Nakorchevsky A. Proteomics by mass spectrometry: approaches, advances, and applications. Annu Rev Biomed Eng. 2009;11:49-79.
38. Becker CH, Bern M. Recent developments in quantitative proteomics. Mutat Res. 2011;722:171-182.
39. Brewis IA, Brennan P. Proteomics technologies for the global identification and quantification of proteins. Adv Protein Chem Struct Biol. 80:144.
40. Yadav AK, Bhardwaj G, Basak T, et al. A systematic analysis of eluted fraction of plasma post immunoaffinity depletion: implications in biomarker discovery. PLoS One. 6:e24442.
41. Vogelsang MS, Sarracino DA, Krastins B, et al. Advantages of a Two-Pass Work flow in Proteomics-based Biomarker Discovery Studies using Plasma or Serum Samples. [Online Poster abstract] International HUPO meeting, September 2012. Available at: https://netforum.avectra.com/eweb/DynamicPage.aspx?Site= HUPO&WebCode=hupo-program. Accessed October 19, 2012.
42. Lopez MF, Sarracino DA, Prakash A, et al. Discrimination of ischemic and hemorrhagic strokes using a multiplexed, mass spectrometry-based assay for serum apolipoproteins coupled to multi-marker ROC algorithm. Proteomics Clin Appl. 2012;6:190-200.
43. Ning M, Gonzalez G. A 69-year-old man with dizziness and vomiting-diagnosis, treatment and prevention of neurovascular disease. N Engl J Med. 2012.
44. Lidegaard O. Oral contraceptives, pregnancy and the risk of cerebral thromboembolism: the influence of diabetes, hypertension, migraine and previous thrombotic disease. Br J Obstet Gynaecol. 1995;102:153-159.
45. Musolino R, La Spina P, Granata A, et al. Ischaemic stroke in young people: a prospective and long-term follow-up study. Cerebrovasc Dis. 2003;15:121-128.
46. Tzourio C, Tehindrazanarivelo A, Iglesias S, et al. Case-control study of migraine and risk of ischaemic stroke in young women. BMJ. 1995;310:830-833.
47. Carolei A, Marini C, De Matteis G. History of migraine and risk of cerebral ischaemia in young adults. The Italian National Research Council Study Group on Stroke in the Young. Lancet. 1996;347:1503-1506.
48. Henrich JB, Horwitz RI. A controlled study of ischemic stroke risk in migraine patients. J Clin Epidemiol. 1989;42:773-780.
49. Merikangas KR, Fenton BT, Cheng SH, et al. Association between migraine and stroke in a large-scale epidemiological study of the United States. Arch Neurol. 1997;54:362-368.
50. Etminan M, Takkouche B, Isorna FC, et al. Risk of ischaemic stroke in people with migraine: systematic review and meta-analysis of observational studies. BMJ. 2005;330:63.
51. Fishman AP, Pietra GG. Handling of bioactive materials by the lung (second of two parts). N Engl J Med. 1974;291:953-959.
52. Fishman AP, Pietra GG. Handling of bioactive materials by the lung (first of two parts). N Engl J Med. 1974;291:884-889.